Solasia Pharma K.K.

DB:9SO Stock Report

Market Cap: €51.9m

Solasia Pharma K.K Past Earnings Performance

Past criteria checks 0/6

Solasia Pharma K.K has been growing earnings at an average annual rate of 14.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 12.1% per year.

Key information

14.3%

Earnings growth rate

22.9%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-12.1%
Return on equity-55.0%
Net Margin-1,265.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Solasia Pharma K.K makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:9SO Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2496-1,215843412
30 Jun 24160-1,286904434
31 Mar 24408-1,1811,025386
31 Dec 23617-1,1121,073403
30 Sep 231,209-1,2671,522425
30 Jun 231,432-1,7381,801728
31 Mar 231,199-2,1742,025799
31 Dec 221,092-2,5482,250883
30 Sep 22761-2,4162,119789
30 Jun 22470-2,3312,091575
31 Mar 22581-2,4372,019764
31 Dec 21559-2,4781,948845
30 Sep 21450-4,3012,7141,747
30 Jun 21492-4,2492,5731,826
31 Mar 21389-4,2522,4751,931
31 Dec 20454-4,1272,4321,928
30 Sep 201,306-2,1321,8401,425
30 Jun 201,420-2,0461,9261,402
31 Mar 201,405-1,8381,9481,150
31 Dec 191,310-1,8671,8681,138
30 Sep 19499-2,5611,4911,286
30 Jun 19364-2,5991,2751,435
31 Mar 19372-2,6621,1981,555
31 Dec 18318-2,4221,0611,463
30 Sep 18111-2,1298881,275
30 Jun 18489-1,378827971
31 Mar 18414-1,086701798
31 Dec 17410-1,007647773
30 Sep 17709-493628512
31 Dec 16501-762488475
31 Dec 15229-917458473
31 Dec 1411-677476237

Quality Earnings: 9SO is currently unprofitable.

Growing Profit Margin: 9SO is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 9SO is unprofitable, but has reduced losses over the past 5 years at a rate of 14.3% per year.

Accelerating Growth: Unable to compare 9SO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 9SO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).

Return on Equity

High ROE: 9SO has a negative Return on Equity (-55%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:32
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Solasia Pharma K.K. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nobumasa MorimotoMizuho Securities Co., Ltd.
Kyoichiro ShigemuraNomura Securities Co. Ltd.
Dion Stéfan BüchnerPathology Associates Co., Ltd.